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Summary
Background The propagation of prions, the causative agents of Creutzfeldt-Jakob disease and other human prion 
diseases, requires post-translational conversion of normal cellular prion protein to disease-associated forms. The 
antimalarial drug quinacrine (mepacrine) prevents this conversion in vitro, and was given to patients with various 
prion diseases to assess its safety and eﬃ  cacy in changing the course of these invariably fatal and untreatable diseases.
Methods Patients with prion disease were recruited via the UK national referral system and were oﬀ ered a choice 
between quinacrine (300 mg daily), no quinacrine, or randomisation to immediate quinacrine or deferred quinacrine 
in an open-label, patient-preference trial. The primary endpoints were death and serious adverse events possibly or 
probably related to the study drug. This study is registered, ISRCTN 06722585.
Findings 107 patients with prion disease (45 sporadic, two iatrogenic, 18 variant, and 42 inherited) were enrolled, 23 in 
a pilot study and 84 in the main study. Only two patients chose randomisation; 40 took quinacrine during follow-up 
(37 who chose it at enrolment). Choice of treatment was associated with disease severity, with those least and most 
severely aﬀ ected more likely to choose not to receive quinacrine. 78 (73%) patients died: one randomly assigned to 
deferred treatment, 26 of 38 who chose immediate quinacrine, and 51 of 68 who chose no quinacrine. Although 
adjusted mortality was lower in those who chose to take quinacrine than in those who did not, this was due to 
confounding with disease severity, and there was no diﬀ erence in mortality between groups after adjustment. Four of 
40 patients who took quinacrine had a transient response on neurological rating scales. Only two of 14 reported 
serious adverse events were judged quinacrine-related. 
Interpretation Quinacrine at a dose of 300 mg per day was reasonably tolerated but did not signiﬁ cantly aﬀ ect the 
clinical course of prion diseases in this observational study. 
Funding Department of Health (England); UK Medical Research Council.
Introduction
No therapeutic intervention prevents or reverses the 
progressive and ultimately fatal course of human prion 
diseases, a group of sporadic, acquired, and inherited 
neurodegenerative disorders characterised clinically by 
cognitive, neuropsychiatric, and motor dysfunction.1 
Prion diseases are highly heterogeneous in clinical and 
pathological phenotypes. The commonest form is 
sporadic Creutzfeldt-Jakob disease (CJD), which aﬀ ects 
about 1–2 people per million annually worldwide and 
presents most commonly with rapidly progressive 
dementia and a median survival of 4–6 months.1 Acquired 
prion diseases have developed after treatment with 
human cadaveric pituitary derived hormones, surgery 
involving contaminated neurosurgical instruments, dura-
mater grafts or corneal transplants, mortuary feasts in 
Papua New Guinea, and, in variant CJD, through exposure 
to prions from cows with bovine spongiform 
encephalopathy and through blood transfusion.2,3 
Inherited prion diseases occur as a result of one of the 
more than 30 known mutations in the prion protein gene, 
PRNP. These dominantly inherited disorders of high 
penetrance account for about 15% of identiﬁ ed human 
prion disease, presenting with various clinicopathological 
syndromes including classic CJD, Gerstmann-Sträussler-
Scheinker disease, and fatal familial insomnia.1
The neuropathological processes underlying these 
diseases are associated with post-translational conversion 
of normal cellular prion protein, PrPC, to abnormal 
disease-associated forms of the same protein, PrPSc, 
through conformational change and aggregation. Many 
experimental therapeutic approaches have been assessed 
with prevention of PrPSc formation in cell and animal 
models as a surrogate marker, even though accumulation 
of PrPSc does not necessarily correlate with neurotoxicity.4,5 
In prion-infected cultured mouse cells, several 
compounds, including quinacrine (mepacrine), block 
PrPSc production.6,7 Extensive clinical experience of 
treating both malaria and rheumatoid arthritis has shown 
that oral quinacrine is safe and can cross the blood–brain 
barrier; therefore, the drug is potentially useful in the 
treatment of human prion disease.7 Interest in this 
potential treatment grew, and some patients requested 
immediate access to quinacrine. The Chief Medical 
Oﬃ  cer asked the Medical Research Council to sponsor a 
clinical trial in prion disease and to investigate any 
therapeutic potential of quinacrine. While the study was 
being prepared, a pilot study was developed allowing all 
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patients requesting quinacrine to receive it with 
appropriate medical monitoring.
Given the relentless and often rapid progression, 
invariably fatal outcome, and lack of other treatment 
options for prion neurodegeneration, randomisation to 
placebo was not likely to be acceptable to many patients 
or their families and carers. Because many patients with 
human prion disease are incapacitated at the time of 
diagnosis, family and carers have an important role in 
decisions about participation in a research study. A 
formal consultation process in the UK with patients, 
families, carers, and representatives of patients was done 
to develop an acceptable study protocol.8 After this 
consultation, PRION-1 was designed as a patient-
preference trial in which patients were given the option 
of random treatment allocation9 to investigate the use of 
quinacrine in all forms of prion disease in the UK.
Methods
Patients
To ensure that PRION-1 enrolled a suﬃ  cient number of 
patients, recruitment of a high proportion of all UK 
patients with prion disease was needed because of the 
rarity of the diseases. A national referral system was set 
up to recruit patients while continuing to support ongoing 
epidemiological studies and surveillance. In 2004, all UK 
neurologists were asked by the Chief Medical Oﬃ  cer to 
refer all patients with suspected prion disease jointly to 
the National CJD Surveillance Unit (Edinburgh, UK) and 
to the National Prion Clinic (London, UK), enabling 
participation in research, including the PRION-1 trial. 
Before the formal launch of PRION-1, patients attending 
the National Prion Clinic could enter a pilot phase of the 
trial in which randomisation was not oﬀ ered. Patients 
with any form of human prion disease who met standard 
diagnostic criteria10 and who were aged 12 years or older 
were eligible. Individuals with known hypersensitivity to 
quinacrine, who had taken any other potential antiprion 
drug within the past 2 months, or who clinicians judged 
to be in a terminal disease state were ineligible. All 
referred patients or their carers were contacted to ask if 
they would agree to a home or clinic screening visit from 
the PRION-1 team. Patients were seen at enrolment and 
subsequently either at the National Prion Clinic or at their 
homes by the same members of the PRION-1 clinical 
team. The PRION-1 trial was approved by the Eastern 
221 referred to National Prion 
Clinic in the main trial
84 enrolled in the main trial
1 chose random allocation
0 assigned immediate 
quinacrine
1 assigned quinacrine
deferred for 24 weeks
1 never started quinacrine
1 died 28 died
1 withdrew consent 
51 died
2 withdrew consent 
0 alive at last follow-up 11 alive at last follow-up 15 alive at last follow-up
1 never started quinacrine
32 started within 7 days
4 started within 18–28 days
1 started >9 weeks later
65 never started quinacrine
1 started 9 weeks later after 
randomisation‡
2 started >9 weeks later
24 chose immediate quinacrine 59 chose no quinacrine
105 not enrolled: ineligible
24 died before screening visit
24 judged terminal, not visited
20 not conﬁrmed as prion disease
37 at risk only, not yet diagnosed*
32 not enrolled: eligible
29 did not consent
3 died before enrolment visit
14 added from pilot† 9 added from pilot†
Figure 1: Trial proﬁ le 
*Relative with symptomatic inherited prion disease or recipient of blood transfusion. †From September, 2001–June, 2002, six patients received open-label quinacrine 
in an initial pilot study, and from August, 2002, to March, 2004, 17 more were oﬀ ered quinacrine or no quinacrine in an extended pilot study (total 23 patients). 
‡One originally chose not to take quinacrine but later agreed to randomisation 9 weeks after enrolment and was allocated immediate quinacrine.
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Multicentre Research Ethics Committee. All patients gave 
consent, or assent was provided by a family member or 
independent neurologists. 
Study design 
PRION-1 was an open-label patient-preference trial in 
which patients were given the option of random 
allocation to treatment, with a planned recruitment of 
160 individuals over 2 years and a minimum follow-up 
of 1 year (ﬁ gure 1). The objective was to obtain data on 
the eﬀ ect of quinacrine in human prion disease, from a 
randomised comparison where acceptable and 
otherwise from observational comparisons. Patients 
who were willing (or, in the case of incapacity, those 
whose advocates or relatives were willing for them to 
be) were randomly allocated: either to immediate or 
deferred (for 6 months) quinacrine. Those patients, or 
their relatives or advocates in cases of incapacity, who 
were not willing to be randomised could choose either 
to take quinacrine immediately or not. 
Patients were assessed at baseline and follow-up at 1, 2, 
4, and 6 months and then after intervals of 3 months. 
Neurological assessments and investigations included 
full blood count and biochemistry, a standardised clinical 
and neurological examination, cognitive assessment 
(mini mental state examination [MMSE], range 0–30;11 
cognitive component of the Alzheimer’s disease 
assessment scale [ADAS-cog], range 0–75;12 Glasgow 
coma score [GCS], range 3–15),13 clinical dementia rating 
(CDR sum of scores, range 0–18),14 the clinician-interview-
based impression of change plus carer input (CIBIC-P-
plus) component of the clinician’s global impression of 
change (range 1–7),15 brief psychiatric rating scale (BPRS 
version 4, range 24–168),16 Rankin scale (range 1–5),17 and 
Barthel activities of daily living index18 (range 0–20). 
Randomisation was stratiﬁ ed by inherited versus other 
prion disease; pre-prepared lists were computer generated 
and sequentially numbered and securely incorporated 
within the trial database. To randomly assign treatment, 
PRION-1 clinicians were to contact the Medical Research 
All patients* Chose 
quinacrine at 
enrolment
Chose no 
quinacrine at 
enrolment†
p value‡ Chose quinacrine 
vs no quinacrine
OR (95% CI; p)§
Enrolled 107 (100%) 32 (100%) 69 (100%)
Studies 0·16
Pilot study 23 (22%) 8 (25%) 9 (13%)
Main study 84 (78%) 24 (75%) 60 (87%)
Type of prion disease 0·06 ··
Sporadic 45 (42%) 8 (25%) 36 (52%)
Iatrogenic 2 (2%) 1 (3%) 1 (1%)
Variant 18 (17%) 6 (19%) 10 (14%)
Inherited 42 (39%) 17 (53%) 22 (32%)
Median age (years; range) 56 (14–82) 55 (17–75) 58 (19–82) 0·18 ··
Non-inherited disease 60 (14–82) 60 (17–75) 62 (19–82)
Inherited disease 43 (32–72) 53 (32–65) 41 (32–72)
Median time (months) since ﬁ rst symptoms¶ (range) 10 (1–140) 13 (2–118) 8 (1–140) 0·04 ··
Non-inherited disease 7 (1–50) 9 (2–19) 7 (1–50)
Inherited disease 26 (3–140) 25 (4–118) 27 (3–140)
Barthel index 1·89 (0·97–3·62; 0·06)
Number assessed 95 (89%) 28 (88%) 67 (97%) 0·08
Median (IQR) 4 (11–17) 14 (5–18) 2 (0–12) 0·0007
MMSE 1·29 (1·06–1·57; 0·01)
Number assessed 58 (54%) 26 (81%) 27 (39%) 0·0001
Median (IQR) 20 (15–25) 23 (18–26) 18 (14–25) 0·20
Median observed/imputed value (IQR)|| 7 (0–21) 22 (7–25) 0 (0–15) <0·0001
CDR 0·64 (0·44–0·92; 0·02)
Number assessed 75 (70%) 27 (84%) 42 (61%) 0·02
Median (IQR) 8 (4–12) 6 (2–8) 9 (6–13) 0·01
Median observed/imputed value (IQR)|| 11 (6–18) 7 (3–10) 16 (8–18) 0·0007
GCS ··
Number assessed 74 (69%) 19 (59%) 54 (78%) 0·06
Median (IQR) 12 (10–14) 15 (11–15) 12 (9–14) 0·001
Median observed/imputed value (IQR)|| 14 (11–15) 15 (14–15) 13 (10–15) <0·0001
(Continues on next page)
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Council Clinical Trials Unit by telephone. Quinacrine 
was given orally with a loading dose of 1 g over 24 h 
(200 mg every 6 h), followed by 100 mg three times daily. 
Because quinacrine produces a characteristic skin 
discolouration, a double-blind comparison was not 
possible, and all patients, carers, clinicians, and nurses 
therefore knew whether or not patients were receiving 
quinacrine. A standardised digital video recording, 
converted to black and white, of the clinical and 
neurological examination was taken by the trial physician 
and scored by an independent assessor who was unaware 
of the treatment allocation. Video recordings were 
reviewed in random order for each patient. 
The primary eﬃ  cacy endpoints were death and 
treatment response, deﬁ ned in the protocol as either 
clinical improvement or lack of deterioration on the 
digital recording of the neurological examination, the 
CIBIC-P-plus, and the BPRS. Because the BPRS could be 
recorded at only 28% of assessments, and because it was 
commonly impossible to assign an overall assessment of 
response across the many domains of the digital 
All patients* Chose 
quinacrine at 
enrolment
Chose no 
quinacrine at 
enrolment†
p value‡ Chose quinacrine 
vs no quinacrine
OR (95% CI or p)§
(Continued from previous page)
ADAS-cog
Number assessed 37 (35%) 20 (62%) 17 (25%) 0·0004
Median (IQR) 17 (8–29) 18 (8–26) 16 (8–32) 0·95 ··
BPRS ··
Number assessed 37 (35%) 19 (59%) 18 (26%) 0·002
Median (IQR) 33 (30–40) 37 (30–40) 32 (30–40) 0·46
Rankin scale
Number assessed 105 (98%) 32 (100%) 67 (97%) 1·00
No or slight symptoms (1/2)** 13 (12%) 5 (16%) 8 (12%) 0·0007 1·00 (0·09)
Moderate disability (3) 21 (20%) 11 (34%) 9 (13%) 3·21 (0·71–14·5)
Moderate to severe disability (4) 31 (30%) 12 (38%) 15 (22%) 5·20 (0·90–30·0)
Severe disability (5) 40 (38%) 4 (12%) 35 (52%) 1·52 (0·17–13·5)
CIBIC-P
Number assessed 105 (98%) 31 (97%) 68 (99%) 0·54
Normal or borderline (1/2)** 7 (7%) 1 (3%) 6 (9%) 0·0001 1·00 (0·07)
Mildly ill (3) 11 (10%) 7 (23%) 4 (6%) 12·8 (1·06–155)
Moderately ill (4) 23 (22%) 11 (35%) 10 (15%) 11·6 (1·04–130)
Markedly ill (5) 26 (25%) 9 (29%) 14 (21%) 14·3 (0·91–222)
Severely ill or the most ill (6/7) 38 (36%) 3 (10%) 34 (50%) 3·39 (0·13–85·5)
Data are number (%) unless otherwise stated. MMSE=mini-mental state examination. CDR=clinical dementia rating. GCS=Glasgow coma scale. ADAS-cog= Alzheimer’s 
Disease Assessment scale cognitive component. BPRS=brief psychiatric rating scale. CIBIC-P=clinician interview-based impression of change plus carer input. *Includes the 
ﬁ rst six patients who received quinacrine in a pilot study without the option of no quinacrine who are excluded from comparisons according to choice. †One patient who 
chose to be randomised at enrolment is included in the chose no quinacrine group (the other randomised patient chose no quinacrine at enrolment, see Results). ‡Univariate 
p values from exact tests (categorical) or ranksum (continuous) assessing the eﬀ ect of each factor on choice of quinacrine or no quinacrine. §Multivariate independent 
predictors; the best multivariate logistic models adjusted for baseline Rankin score or CIBIC-P and one of Barthel index, MMSE, and CDR; numbers were too small to 
discriminate further between these predictors; eﬀ ect on choice of quinacrine versus no quinacrine shown for Rankin and MMSE (OR per 3 units higher) from model including 
Rankin and MMSE, for CDR and Barthel index (OR per 3 units higher) from model including Rankin and CDR or Barthel index, and for CIBIC-P from a model including CIBIC-P 
and MMSE (similar results were obtained for other models combining these factors), absence of OR means no evidence of a independent contribution of this factor (p>0·10). 
¶Excluding six patients asymptomatic at enrolment (one chose quinacrine, ﬁ ve chose no quinacrine). ||Methods for imputation strategy; number of imputed baseline 
values: MMSE 48, CDR 30, GCS 32. **Percentages of non-missing values.
Table 1: Characteristics at enrolment: overall and according to initial choice of quinacrine or not
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recording, a revised deﬁ nition of response was agreed by 
the trial steering committee, namely improvement on 
two or more clinical rating scales with no deterioration 
on all the other rating scales used at the same time point 
where improvement or lack of deterioration had been 
predeﬁ ned for each rating scale in the protocol. The 
primary safety endpoint was any serious adverse event 
not known to be or likely to be related to prion disease 
and considered possibly or probably related to quinacrine, 
with serious events deﬁ ned as fatal, life threatening, 
requiring or increasing the length of time in hospital, or 
resulting in persistent or signiﬁ cant disability or other 
important medical events. Serious adverse events in the 
PRION-1 trial (from April, 2004) were independently 
reviewed by a member of the trial steering committee. 
Toxicity grades were deﬁ ned according to the National 
Cancer Institute common toxicity criteria (version 2.0)19 
with minor modiﬁ cations. There was no requirement to 
report a laboratory grade 4 adverse event as a serious 
adverse event unless it met the clinical criteria for 
seriousness. 
Statistical analysis
Kaplan–Meier plots, log-rank tests, and Cox proportional 
hazards models were used to compare groups for time-
to-event outcomes. Categorical variables were compared 
with exact tests, and continuous variables with t tests and 
rank-sum tests. Baseline values were those recorded 
before and nearest to enrolment (all within the preceding 
9 days). The closest measurement to the scheduled 
assessment week within equally spaced time windows 
was used subsequently. Missing MMSE or CDR values 
were imputed as the worst score (0 or 18, respectively) if 
GCS was 14 or lower, and missing GCS was imputed as 
the best score (15) if MMSE was 5 or higher. Logistic 
models for initial preference of quinacrine versus no 
quinacrine used multiple imputation with chained 
estimation combining results from 50 imputations for 
remaining missing baseline values (in six of 101 patients) 
with Rubin’s rules20 or analyses of survival. Follow-up 
time for each patient was split into before and after 
quinacrine periods (cohort analysis), counting time from 
enrolment and using late entry for patients initiating 
Univariate eﬀ ect on risk of mortality Multivariate eﬀ ect on risk 
of mortality* (model 1)
Multivariate eﬀ ect on risk of 
mortality* (model 2)
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Quinacrine use† 0·52 (0·31–0·86) 0·01 1·10 (0·60–2·01) 0·76 0·98 (0·56–1·71) 0·94
Sex 0·71 (0·45–1·12) 0·14 0·42 (0·25–0·72) 0·002 0·47 (0·28–0·77) 0·003
Age (per 10 years) 1·68 (1·40–2·01) <0·0001 1·31 (1·10–1·56) 0·002 1·32 (1·12–1·57) 0·001
Months since ﬁ rst symptoms‡ (per 12 months) 0·70 (0·58–0·85) 0·0003 ·· ·· ·· ··
Inherited prion disease 0·13 (0·07–0·24) <0·0001 0·26 (0·13–0·53) 0·0002 0·24 (0·12–0·47) <0·0001
Period of study: pilot 0·35 (0·18–0·68) 0·02 ·· ·· ·· ··
April, 2004, to March, 2005 (main trial) 1·00
April, 2005, to December, 2005 0·82 (0·47–1·44)
2006 0·85 (0·44–1·64)
MMSE (per 3 units higher) 0·79 (0·74–0·85) <0·0001 ·· ·· ·· ··
Rankin scale <0·0001 0·03 ·· ··
No or slight symptoms 1·00 1·00
Moderate disability 1·03 (0·26–4·11) 0·45 (0·11–1·89)
Moderate to severe disability 7·35 (2·29–23·6) 1·45 (0·35–6·08)
Severe disability 14·9 (4·65–47·5) 2·52 (0·56–11·3)
GIC <0·0001 ·· ·· ·· ··
Normal, borderline, mildly ill§ 1·00
Moderately ill 2·33 (0·78–6·96)
Markedly ill 8·54 (3·05–23·9)
Severely ill 17·1 (5·97–49·2)
Amongst the most ill 18·0 (6·18–52·3)
Barthel index (per 3 units higher) 0·65 (0·57–0·73) <0·0001 ·· ·· ·· 0·80 (0·67–0·96) 0·02
CDR (per 3 units higher) 1·68 (1·46–1·93) <0·0001 ·· 1·25 (1·02–1·52) 0·03 1·19 (0·98–1·45) 0·08
GCS (per 3 units higher) 0·39 (0·31–0·49) <0·0001 ·· ·· ·· ·· ··
MMSE=mini-mental state examination. GIC=global impression of change. CDR=clinical dementia rating, GCS=Glasgow coma scale. *Unstratiﬁ ed adjusted model: numbers 
were too small to unambiguously identify independent predictors. †Time-updated variable: whether a patient had already taken quinacrine in PRION-1 versus never or not 
yet initiated. ‡For asymptomatic patients (n=6), months since ﬁ rst symptoms imputed as 2 years more than the maximum observed. §All patients classed “normal” or 
“borderline” by GIC (n=7) were alive at the end of the study, and therefore to ﬁ t models this group is combined with the mildly ill (n=11). Absence of OR means no evidence of 
a signiﬁ cant independent contribution of this factor (p>0·10).
Table 2: Predictors of mortality
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quinacrine after enrolment. For adverse events, time at 
risk was classiﬁ ed by whether or not patients were on 
quinacrine or had taken it in the last 30 days. All p values 
are two-sided. The original sample size for the randomised 
comparison of 87 patients was designed to provide at least 
80% power to detect a reduction in 2 year mortality from 
50% to 22% (hazard ratio 0·35, two-sided α=0·05).
This study is registered, ISRCTN 06722585.
Role of the funding source
The sponsor had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
From September, 2001, to June, 2002, six patients received 
open-label quinacrine in the pilot study; from August, 
2002, to March, 2004, 17 were oﬀ ered a choice of quinacrine 
or no quinacrine in an extension of this pilot study. From 
April, 2004, to August, 2006, 84 patients enrolled in the 
main PRION-1 trial. All patients were followed up until 
March 31, 2007. 107 patients, 50 (47%) of whom were male, 
were recruited in the pilot or main study (ﬁ gure 1). 38% of 
referred and 72% of eligible patients were enrolled. Only 
one patient chose random allocation of treatment at 
enrolment and was allocated to deferred quinacrine but 
chose not to start quinacrine at 24 weeks. A second patient 
chose not to take the drug at enrolment, but subsequently 
opted for random allocation at week 9; this patient 
commenced immediate quinacrine. Consequently 
PRION-1 is primarily an observational study of patients 
who chose the drug or did not. 
Table 1 lists the characteristics at enrolment of all 
patients according to the patient’s initial preference for 
quinacrine or no quinacrine when this choice was 
oﬀ ered. A deﬁ nitive diagnosis (genetic mutation or tissue 
examination including tonsil biopsy at screening or post-
mortem examination) was made in 78 (73%) patients: 
none was wrongly diagnosed. In total, 38 patients chose 
quinacrine at enrolment, of whom 37 received the drug. 
69 patients chose no quinacrine initially; three of them 
took the drug at some point during follow-up (ﬁ gure 1). 
One patient who chose quinacrine had previously taken 
the drug for 3 weeks from 5 weeks before enrolment and 
was enrolled in error. This patient was included in the 
analysis. 
In univariate analyses, MMSE was the most important 
predictor of choice of quinacrine, with all other neurological 
rating scales and inherited versus other human prion 
disease also signiﬁ cant univariable predictors. However, 
these baseline factors were all strongly associated with 
each other, and the number of participants was too small 
to unambiguously identify independent predictors of 
opting for quinacrine. The best models indicated that both 
the most and least severely aﬀ ected patients (by either 
CIBIC-P or Rankin scale) were least likely to choose 
quinacrine. Those patients with better MMSE, Barthel 
index, or CDR scores were independently signiﬁ cantly 
more likely to choose the drug than were those with similar 
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symptoms by type of human prion disease (C).
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scores on the CIBIC-P or Rankin scale (table 1). Thus, 
unadjusted comparisons of patients choosing to take or 
not take quinacrine are confounded by disease severity.
40 patients received quinacrine, with four starting 
9 weeks or more after enrolment (ﬁ gure 1). Overall, 46% 
of person-time at risk before death or end of study was 
spent on quinacrine (at any dose) after starting it 
(ﬁ gure 2), with a Kaplan–Meier median 7·4 months 
(1·7–14·8) to permanent discontinuation. Five (12%) 
patients were still alive and taking quinacrine at the end 
of the study (three on 100 mg daily, two on 200 mg daily). 
24 (60%) patients reduced drug dose (12 alive at end of 
study including the ﬁ ve still taking quinacrine), 11 (28%) 
permanently discontinued quinacrine 300 mg daily 
(three alive at end of study), and ﬁ ve (12%) continued on 
their initial 300 mg dose until they died. Two patients 
who chose not to receive the study drug took other 
putative antiprion drugs during PRION-1: one took 
ﬂ upirtine from 3 weeks to 7 weeks after enrolment, and 
the other took pentosan polysulfate from 4 weeks to 
60 weeks; when they withdrew consent. 
78 (73%) patients died (34 within 6 weeks of enrolment), 
26 (68%) of 38 who initially chose quinacrine (one died 
before starting the drug) and 52 (75%) of 69 who initially 
chose no quinacrine (including the one patient who was 
randomised to no quinacrine). The median follow-up in 
the 29 patients not known to have died was 16 months 
(IQR 12–25); three withdrew consent.
Although unadjusted mortality seemed lower in 
patients choosing to take quinacrine (table 2, ﬁ gure 3), 
this was a consequence of substantial confounding 
between choosing treatment and baseline characteristics, 
particularly inherited versus other types of prion disease 
and scores on neurological rating scales, which were all 
strong independent predictors of mortality (p<0·0001, 
table 2). After adjusting for the low mortality risk in 
women, young patients, those with inherited prion 
disease, and those with better clinical or neurological 
status at baseline (either by Rankin scale, CDR, or Barthel 
index), there was no signiﬁ cant diﬀ erence in survival 
(ﬁ gure 3) between patients who took quinacrine and 
those who did not after enrolment, stratiﬁ ed by baseline 
Rankin scake (hazard ratio [HR] 0·87, 95% CI 0·49–1·52; 
p=0·62) or survival from reported time of ﬁ rst symptoms 
stratiﬁ ed by type of prion disease (1·14, 0·69–1·89; 
0·61).
Deﬁ ning response as improvement on two or more 
neurological rating scales without deterioration in any 
other scales measured at the same time point 
(improvement or deterioration predeﬁ ned in the 
After enrolment and before quinacrine 
initiation
After quinacrine initiation After quinacrine initiation: 
adverse-event reported
Total Last seen 
alive
Last seen 
dead
Total Last seen 
alive
Last seen 
dead
Total Last seen 
alive
Last seen 
dead
Response 1 (0/1)* 1 (0/1) ·· 4 (1/3)† 3 (0/3) 1 (1/0) 4 (1/3) 3 (0/3) 1 (1/0)
Stable 17 (7/10) 10 (1/9) 7 (6/1) 4 (2/2) 1 (0/1) 3 (2/1) 3 (2/1) 1 (0/1) 2 (2/0)
Deterioration 24 (15/9) 7 (3/4) 17 (12/5) 28 (10/18) 11 (1/10) 17 (9/8) 24 (7/17) 11 (1/10) 13 (6/7)
Baseline data only* 29 (27/2) ·· 29 (27/2) 4 (4/0) ·· 4 (4/0) ·· ·· ··
Total 71 (49/22) 18 (4/14) 53 (45/8) 40 (17/23) 15 (1/14) 25 (16/9) 31 (10/21) 15 (1/14) 16 (9/7)
Data are number (number with non-inherited disease/number with inherited disease). For each individual rating scale, response was predeﬁ ned in the protocol as an increase 
of 3 units on the mini-mental state examination, 2 units on the Barthel index, or 2 units on the Glasgow coma scale, and a decrease of 1 unit on the Rankin scale, 3 units on 
clinical dementia rating (CDR), 1 unit on global impression of change (GIC), 10 units on Alzheimer’s Disease Association-cognitive component, and 6 units on the brief 
psychiatric rating scale. Deterioration was deﬁ ned as the inverse (decrease or increase respectively); those not meeting criteria for either response or deterioration were 
deﬁ ned as stable. Overall response is deﬁ ned as response on two or more of the neurological rating scales, without deterioration on any other scores measured at the same 
timepoint at any time during follow-up. *Response compared with baseline at all visits from week 37 through 113 (last seen alive). †Response at one or two visits only 
followed by deterioration before date last seen alive or death.
Table 3: Overall response based on neurological rating scales
Quinacrine Human prion 
disease
Response at 
weeks*
GCS
range 3–15
Rankin
range 1–5
GIC
range 1–7
BPRS
range 24–168
Barthel
range 0–20
Died week 52 Yes Sporadic 4 11→13 4→3 ·· ·· ··
Alive week 167 Yes Inherited 17, 40† ·· 3→2 4→3 ·· ··
Alive week 104 Yes Inherited 11 ·· 3→2 ·· 42→25 ··
Alive week 65 Yes Inherited 4, 28‡ ·· 3→2 4→3 39→25 ··
Alive week 113 No Inherited 24–113 ·· 4→3 4→2-3 ·· 10→12–15
High scores are favourable on Glasgow coma scale and Barthel index and low scores are favourable on Rankin scale, global impression of change (GIC), and brief psychiatric 
rating scale. *Weeks after quinacrine initiation for those with response on quinacrine, otherwise weeks from enrolment. †One intervening visit without response. ‡Three 
intervening visits without response. Missing data indicate no change or value not measured.
 Table 4: Details of responders
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protocol), four of 40 patients who took immediate 
quinacrine had a transient response at one or two visits 
after treatment started (all four experienced quinacrine-
related toxicity), compared with one of 71 patients before 
quinacrine initiation (table 3). This patient had improved 
from 24 weeks after enrolment throughout follow-up to 
week 113 when last seen alive, suggesting that the data 
recorded at the enrolment visit might inaccurately 
represent baseline status for this patient (table 4).
14 serious adverse events were reported in 11 patients, 
nine in seven patients taking quinacrine at the time or in 
the preceding 30 days (table 5). Ten serious adverse 
events (ﬁ ve on study drug) required hospital admission. 
At independent review, seven of the 13 serious adverse 
events during the main trial phase were judged deﬁ nitely 
or probably related to prion disease, and only two of the 
remaining six were thought possibly or probably related 
to quinacrine (a tonic-clonic seizure on day 3 and 
aspiration pneumonitis on day 6 of treatment). 17 grade 3 
or 4 adverse events were reported in 16 patients on 
quinacrine, 11 of which were thought possibly or probably 
related to the drug including ﬁ ve raised results on liver-
Reported serious 
adverse events 
Independently 
adjudicated* serious 
adverse events 
Reported grade 3 or 4 
adverse events 
Reported adverse events (any 
grade) leading to quinacrine 
discontinuation or dose reduction 
On† Oﬀ  On† Oﬀ  On† Oﬀ  
Rash 2 (2) 9
Yellow skin 1
Dry skin 1
Grand mal convulsion or seizure 2 (2) 1 (1) 2 (2) 1
Haematemesis 1 (1) 2
Haematuria and haematemesis 1 (1) 1 1 (1) 1
Abdominal wall abscess 1 1 1
Diarrhoea 1
Nausea 1 (1) 3
Nausea and delirium 1
Nausea and diarrhoea 1
Nausea and diarrhoea and high alanine 
aminotransferase concentrations
1
Nausea and paraesthesia 1
Vomiting and dysphagia 1 1 1
Vomiting and aspiration pneumonitis 1 (1) 1 (1) 1
Aspiration pneumonia 2 2 1
Liver-function test abnormal 2 (2) 2
Alanine aminotransferase increased 3 (3) 16
Aspartate aminotransferase increased 2
Alkaline phosphatase increased 2
Lower-respiratory-tract infection 1 1 1
Pneumonia bacterial and lung consolidation 1 1
Urinary-tract infection bacterial 1
Suicide attempt 1 1 1
Fracture and pneumothorax traumatic 1
Laceration 1 1
Aggression 1 1
Abnormal behaviour 1
Agitation and somnolence 1
Other‡ 3
Total events 9 (5) 5 4 (2) 2 17 (11) 5 53
Rate per 100 patient-months 2·9 (1·6) 0·7 1·8 (0·9) 0·3 5·5 (3·6) 0·7 25·4
Total patients 7 (4) 4 4 (2) 2 16 (10) 4 30
Data are number of events, with those judged as probably or possibly related to quinacrine in parentheses. Diﬀ erence between on and oﬀ  quinacrine in rate of all reported 
serious adverse events (p=0·006) and all grade 3/4 adverse events (p<0·0001). All reported serious adverse events were also grade 3 or 4 events except for haematemesis 
(grade 2) and vomiting and aspiration pneumonitis (reported as grade 1 vomiting and dyspnoea but judged grade 4 aspiration pneumonitis at independent review). 
*Serious adverse events during the main trial were reviewed by an independent trial physician (one aspiration pneumonia during the pilot study was not reviewed). †While 
taking quinacrine or within 30 days of stopping. ‡Acquired pigmented retinopathy, abnormal EEG, and hyponatraemia. 
 Table 5: Grade 3 or 4 and serious adverse events and reactions, and adverse events leading to quinacrine discontinuation or dose reduction
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function tests and two rashes, compared with ﬁ ve grade 3 
or 4 events in four patients oﬀ  quinacrine. However, dose 
modiﬁ cation or discontinuation was more common after 
mostly low-grade adverse events (total 53 adverse events) 
than after serious events, most commonly associated 
with abnormal results of liver-function tests (20 patients), 
rashes (nine), and nausea (seven).
Discussion
After adjusting for the substantial diﬀ erences between 
patients who chose to take quinacrine or not, we did not 
ﬁ nd any evidence that oral quinacrine at a dose of 300 mg 
a day increased the length of survival of patients with 
prion disease. 
The aims of PRION-1 were to assess the risks and 
beneﬁ ts of quinacrine in human prion disease and to 
establish a framework for the clinical assessment of 
future therapeutic options. As the ﬁ rst major prospective 
study with longitudinal assessments in human prion 
disease in the UK, PRION-1 showed that national 
recruitment and retention is feasible and acceptable to 
patients and carers. Availability of dedicated clinical 
teams to visit patients in their local environment and to 
respond rapidly to any referrals was important because 
sporadic and acquired prion diseases are severely 
debilitating and rapidly progressive. However, PRION-1 
highlighted the diﬃ  culty of randomised controlled trials 
in human prion disease. Only two of 84 patients or their 
carers agreed to randomisation, even though the design 
of the trial meant that all participants would receive 
quinacrine either immediately or after an interval in the 
deferred arm. Aﬀ ected patients, or the families and 
carers of individuals who lacked capacity to give consent, 
overwhelmingly preferred to make decisions on 
treatment rather than agree to randomisation. Patients 
and their carers faced with the prospect of a rapidly 
progressive fatal disease were unwilling to accept the 
possibility of randomisation to deferred treatment, 
whereas many families caring for a severely demented 
and physically incapacitated family member were not 
prepared to accept a therapeutic intervention that, at 
best, was expected to slow or halt disease progression 
with little or no prospect of reversing established 
neurological damage. Because no potential treatment is 
likely to reverse neuropathology or clinical status in 
severely aﬀ ected individuals, future trials aimed at mild 
to moderately aﬀ ected patients might oﬀ er the best 
prospect of acceptance of random treatment allocation 
and therefore the ability to reliably assess a new 
treatment.21 There was equipoise, at least at the 
population level if not at an individual level, in patients 
who were mild to moderatly aﬀ ected in PRION-1, in that 
about half chose quinacrine and half chose no quinacrine. 
A further complexity was yellow skin discolouration, 
which prevented a fully blinded study. 
PRION-1 was essentially an observational study of 
patients choosing to take quinacrine or not, in which we 
identiﬁ ed strong determinants of this choice, the most 
important being severity of disease. Although quinacrine 
was associated with a raised incidence of adverse events, 
most were mild and led only to dose reduction or 
discontinuation. These ﬁ ndings are consistent with a 
case–control study in which the survival of 30 patients 
with sporadic CJD who received quinacrine was not 
signiﬁ cantly diﬀ erent from that in control individuals.22 
Smaller series or individual case reports similarly 
describe either no beneﬁ t after quinacrine treatment 
alone or in combination with chlorpromazine23–25 or only 
a transient clinical response with quinacrine.26–28 A 
transient response was noted in four of the 40 patients 
receiving the drug in our study. A more complex analysis 
of the secondary endpoints is underway. Transient clinical 
responses have been reported in individual patients 
treated with amantadine, vidarabine, or levetiracetam, 
and might be due to symptomatic eﬀ ects including non-
speciﬁ c arousal, or suppression of spasticity and 
myoclonus.29–31 No drug prevents disease progression, 
although a slowed rate of cognitive deterioration but no 
eﬀ ect on survival was recorded in 13 patients treated with 
ﬂ upirtine compared with placebo in the only randomised 
double-blind trial in human prion disease.21
One explanation for the lack of beneﬁ t from quinacrine 
in our study is that adequate drug concentrations were 
not achieved at the sites crucial for the antiprion eﬀ ect 
shown in cell models. A 0·3 μmol/L concentration of 
quinacrine, estimated to produce half-maximally eﬀ ective 
inhibition of PrPSc accumulation in cell models, 
corresponds to a concentration of about 120 ng/mL.7,32 
We did not have serum or CSF concentrations of 
quinacrine in this trial, but work related to the treatment 
of malaria suggested steady-state serum concentrations 
of 30–75 ng/mL in patients taking 300 mg quinacrine per 
day.33 Animal studies showed much lower CSF 
concentrations but with evidence of accumulation in 
brain tissue and lysosomes to concentrations matching 
those seen in infected ScN2a cell culture.34–36 
Our experience highlights several challenges to the 
assessment of new treatments for human prion disease. 
First, the rarity of human prion disease emphasises the 
importance of designing trials that are acceptable to as 
many patients as possible to maximise the information 
gained on new drugs. If randomisation that includes a 
group not receiving the new drug is not acceptable to 
patients or their carers, other options, such as patient-
preference trials or comparisons within patients—both 
much more diﬃ  cult to interpret than randomised 
trials—might be the only options. Incorporation of home 
visits is crucial for acceptability to patients with prion 
diseases. Furthermore, the small numbers of patients 
coupled with the subjectivity of many of the neurological 
rating scales means that restricting the number of 
practitioners making assessments is essential to reduce 
interobserver variability. Second, many patients were 
identiﬁ ed only when disease was already advanced. Earlier 
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diagnosis is a high priority if patients are to be included 
in treatment trials, as those with mild to moderate disease 
are probably most likely to accept randomisation. In this 
regard, the sensitivity and speciﬁ city of clinical 
investigations including CSF and other markers of early 
disease need to be more accurately established. New MRI 
techniques, particularly diﬀ usion-weighted imaging and 
ﬂ uid-attenuated inversion-recovery sequences, oﬀ er 
increased sensitivity in neuroimaging of suspected 
disease and might usefully be incorporated in diagnostic 
criteria and criteria deﬁ ning response to new treatments. 
Because patients with prion disease form a heterogeneous 
population and survival is likely to be strongly inﬂ uenced 
by other medical interventions, future treatments should 
be assessed primarily through randomised and adequately 
controlled clinical trials or at least in prospectively 
followed cohort studies. Unless a new treatment has a 
substantial eﬀ ect on clinical response or survival, 
comparison with historical or other similar controls will 
probably not be suﬃ  cient to provide proof of eﬃ  cacy, and 
under these circumstances open-label uncontrolled 
studies provide limited information on toxicity at best.
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